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Abstract
ADAM proteases are type I transmembrane proteins with
extracellular metalloprotease domains. As for most
ADAM family members, ADAM8 (CD156a, MS2) is
involved in ectodomain shedding of membrane proteins
and is linked to inflammation and neurodegeneration.
To identify potential substrates released under these
pathologic conditions, we screened 10-mer peptides
representing amino acid sequences from extracellular
domains of various membrane proteins using the
ProteaseSpot system. A soluble ADAM8 protease con-
taining a pro- and metalloprotease domain was ex-
pressed in E. coli and purified as active protease owing
to autocatalytic prodomain removal. From 34 peptides
tested in the peptide cleavage assay, significant cleavage
by soluble ADAM8 was observed for 14 peptides repre-
senting membrane proteins with functions in inflamma-
tion and neurodegeneration, among them the b-amyloid
precursor protein (APP). The in vivo relevance of the
ProteaseSpot method was confirmed by cleavage of
full-length APP with ADAM8 in human embryonic kidney
293 cells expressing tagged APP. ADAM8 cleaved APP
with similar efficiency as ADAM10, whereas the inactive
ADAM8 mutant did not. Exchanging amino acids at
defined positions in the cleavage sequence of myelin
basic protein (MBP) revealed sequence criteria for
ADAM8 cleavage. Taken together, the results allowed us
to identify novel candidate substrates that could be
cleaved by ADAM8 in vivo under pathologic conditions.
Keywords: ADAM protease; candidate substrates;
ectodomain shedding; fluorescence assay; peptide
cleavage.
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Introduction
ADAMs (a disintegrin and metalloprotease) or MDCs
(metalloprotease disintegrin cysteine-rich proteins) form
a family of type I transmembrane proteins. Owing to their
multidomain structure consisting of pro-, metallopro-
tease, disintegrin-like, cystein-rich, EGF-like, transmem-
brane and cytoplasmic domains, ADAMs are capable of
four physiological functions: cell adhesion, cell fusion,
cell signalling and proteolysis.
They are implicated in physiological processes such as
fertilisation, myogenesis and neurogenesis, and are also
involved in a number of pathological processes by
releasing cytokines and their receptors under inflamma-
tory conditions (Moss and Bartsch, 2004). To date, 40
members are known in different species (table of ADAMs
on http://www.people.virginia.edu/;jw7g/). Approxi-
mately half of these ADAMs contain the catalytic con-
sensus sequence HEXXHHXXGXXHD in their metal-
loprotease domains and are therefore predicted to be
catalytically active. Proteolysis of membrane-an-
chored precursor proteins is a key event in signalling cas-
cades (Blobel, 2005) and this process has been termed
ectodomain shedding (Peschon et al., 1998). A number
of ADAM substrates have been defined either by their
physiological role or by their cellular localisation (Seals
and Courtneidge, 2003; Moss and Bartsch, 2004; Blobel,
2005). So far, no consensus sequence on the substrate
side has been reported, making prediction of potential
cleavage sites difficult. Rather, ADAMs recognise a struc-
tural footprint on the extracellular part of the membrane
protein, and it is assumed that cleavage occurs in the
juxtamembraneous regions of these membrane proteins.
Our particular research interest is the ADAM family
member ADAM8, originally identified as MS2 or CD156
in mouse macrophages (Yoshida et al., 1990). ADAM8 is
expressed in several tissues, such as thymus, cartilage,
bone, brain and spinal cord, during embryonic develop-
ment. As embryonic development of the ADAM8-defi-
cient mouse appears normal, ADAM8 does not seem to
be essential for developmental processes (Kelly et al.,
2005). Rather, it is more likely that ADAM8 has a specific
function in cytokine response. In response to inflamma-
tory stimuli such as lipopolysaccharide (LPS) and tumour
necrosis factor a (TNF-a), ADAM8 expression is upre-
gulated in macrophages and in the central nervous
system (CNS) in activated glia cells – astrocytes and
microglia – indicating its involvement in neuron-glia sig-
nalling (Schlomann et al., 2000). In addition to glial cells,
ADAM8 is expressed in neurons at low levels, and
expression is induced by TNF-a, suggesting that under
inflammatory conditions in the CNS, neuronal ADAM8
activity is significantly increased (Schlomann et al., 2000).
In the lung, ADAM8 is upregulated under experimental
induction of allergic asthma by inflammatory cytokines
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Figure 1 Expression of soluble ADAM8 protease in E. coli.
(A) Time course of recombinant ADAM8 induction; times are giv-
en in h after addition of anhydrotetracycline (aTc) into the medi-
um. Overnight induction (‘ON’) caused a decrease in the amount
of recombinant protein, whereas ‘-’ indicates no induction. (B)
Purification of recombinant ADAM8 from E. coli; lys, total bac-
terial lysate; cf, cytoplasmic fraction; ib, inclusion bodies; 1, 2,
and 3 are different elution fractions after Strep-tag affinity
chromatography; reg, regenerate. Both blots were stained for
ADAM8 using a monoclonal anti-BiPro-tag antibody. The upper
band (ca. 56 kDa) indicated by an arrow corresponds to the
proform of soluble ADAM8 protease, containing the pro- and
metalloprotease domain; the lower band (ca. 33 kDa) matches
with the metalloprotease domain after prodomain removal. (C)
Coomassie Blue-stained SDS-PAGE with total bacterial lysates
(lys) and Strep-tag affinity chromatography eluates (eluate)
from uninduced (-) and aTc-induced (q) E. coli.
(King et al., 2004), suggesting that ADAM8 plays a role
in the pathogenesis of allergic asthma. All these findings
underline the importance of ADAM8 in inflammatory
processes.
Recent attention has focussed on ADAM8 as a mole-
cule upregulated in various tumours. ADAM8 is consid-
ered a prognostic marker for lung adenocarcinomas
(Ishikawa et al., 2004) and renal cell carcinomas (Roemer
et al., 2004). In addition, in brain tumours such as glio-
blastoma, oligoastrocytoma, and ependymoma, ADAM8
expression was increased compared to normal brain
controls, and ADAM8 expression in glioblastoma corre-
lates with malignancy and invasive activity (Wildeboer et
al., unpublished results). In B-cells, ADAM8 cleaves the
low-affinity IgE receptor (CD23, Fc´RII) suggesting a role
in immune modulation (Fourie et al., 2003). Although
ADAM8 seems to impair allergy and inflammation by
ectodomain shedding, only a few substrates of ADAM8
and their corresponding cleavage sites are known
(Amour et al., 2000; Schlomann et al., 2002; Fourie et al.,
2003; Naus et al., 2004). In the present study, we ana-
lysed the ability of ADAM8 to cleave 10-mer peptides
as representatives of the extracellular domains of
membrane proteins involved in immune modulation, in-
flammation, and cell adhesion.
Results
Expression and purification of active ADAM8
protease from E. coli
The bacterial expression vector pASK-IBA3q allows for
expression of recombinant ADAM8 pro-/metalloprotease
(A8ProMP) in the cytoplasma after induction with anhy-
drotetracycline (aTc). Maximal expression rates were
obtained 4–6 h after aTc induction and decreased after
overnight induction, probably owing to instability of the
protein (Figure 1A). Expression of A8ProMP is reflected
by a band of ca. 56 kDa, while a lower band of ca. 33 kDa
represents the entire metalloprotease domain of ADAM8
(A8MP) after prodomain removal.
Approximately two-thirds of the total ADAM8 protein
expressed in E. coli was found in inclusion bodies, and
one-third in the cytoplasmic fraction. This fraction was
taken for further purification using Strep-Tactin columns
(Figure 1B) without any additional treatment to increase
ADAM8 solubility. After elution from the column, one frac-
tion was collected that contained most of the ADAM8
protein (Figure 1B, C). This fraction contained a signifi-
cant amount of processed ADAM8, as monitored by
Western blotting (Figure 1B) and SDS-PAGE (Figure 1C),
and was used in all further studies.
Activity of the recombinant ADAM8 protease
The catalytic activity of recombinant A8MP was tested
using a peptide derived from the cleavage sequence of
human CD23 (DNP-SHHGDQMAQKSQSTQI) in a fluores-
camine assay (Figure 2). Within 4 h of incubation, there
was significant cleavage of the CD23 peptide, whereas
no cleavage was observed in the controls, including a
sample with ADAM8 protease in the presence of EDTA.
A8ProMP isolated from E. coli was not active, demon-
strating that only the entire MP domain confers proteo-
lytic activity (data not shown).
Cleaved peptides were separated by HPLC and sub-
jected to mass spectrometry. The CD23 cleavage site
is located between a glutamine and lysine residue:
QMAQxKSQ (see also Table 1).
ADAM8 peptide substrates
Our focus was to characterise the role of catalytically
active ADAM8 in (neuro-) inflammation. A total of 34 pep-
tides derived from proteins involved in inflammatory
processes and immune response in the nervous system
were selected. In most cases they represent membrane-
proximal sequences.
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Figure 2 Fluorescence determination of ADAM8 activity using
the CD23 peptide DNP-SHHGDQMAQKSQSTQI.
Relative fluorescence intensities were determined initially (ts0),
and after 2 and 4 h by addition of fluorescamine. As controls,
CD23 peptide alone, A8MP alone, or CD23 peptide mixed with
A8MP in the presence of 10 mM EDTA was incubated under
reaction conditions. The peptide assay was repeated at least five
times and the values given are representative of all experiments
performed.
All peptides, with the corresponding proteins and their
accession numbers in the Swiss-Prot/TrEMBL protein
database, are listed in Table 1.
Cleavage assays were performed with A8MP in the
absence or presence of 10 mM EDTA. Fluorescence
increases were monitored over 18 h. In cases of con-
sistent and significant fluorescence increase and no
response in the presence of EDTA, ADAM8-specific clea-
vage was concluded.
The relative fluorescence increase corresponding to
cleavage efficiency was expressed as relative units and
was normalised to the MBP peptide as 1 (Figure 3A).
Relative fluorescence increases of 1 U and higher were
considered as significant ADAM8-specific cleavage. Flu-
orescence increases between 0.5 and 1 U indicate cleav-
age, although at lower levels, given the fact that sig-
nificantly cleavable peptides incubated with A8MP in the
presence of EDTA never exceeded 0.3 U. In addition, the
time dependence of cleavage was monitored for two
selected peptides (APP and CD23.1; Figure 3B). With
these peptides, a clear correlation between the incuba-
tion time and the increase in relative fluorescence inten-
sity was demonstrated.
Summarising the results of the peptide screen, 14 of
34 tested peptides were cleaved by ADAM8, 10 of them
strongly and four to a lesser extent. Among the strongly
cleaved peptides were those derived from b-amyloid pre-
cursor protein (APP), low-affinity IgG receptor (CD16,
Fcg-RIII), low-affinity IgE receptor (CD23, Fc´RII), frac-
talkine CX3CL1, L-selectin, P-selectin glycoprotein
ligand (PSGL-1), transforming growth factor a (TGF-a)
and TNF-a. Furthermore, peptides derived from macro-
phage haemoglobin scavenger receptor (CD163), inter-
leukin-1 receptor type II (IL-1-RII), TNF receptor 1 (TNFRI)
and TNF-related activation-induced cytokine (TRANCE)
were cleaved with lower efficiency. In contrast to data
published by Amour et al. (2002), a peptide derived from
kit ligand (KL) was not cleaved.
For PSGL-1 and CD23, two peptides were cleaved.
The two peptides for PSGL-1 shared overlapping amino
acids, suggesting that a cleavage site might be located
in this overlapping region, which contains the amino
acids KKG. A similar cleavage site was observed for the
TGF-a peptide, which is cleaved at SQxKK and SQKxK.
CD23 is known to be released from the cell surface by
cleavage at three different cleavage sites (Mayer et al.,
2002). ADAM8 cleaves at two of these sites in the two
corresponding peptides. Both of these peptides also
contain glutamine residues, underlining a certain prefer-
ence for amino acid residues.
ADAM8 cleavage of MBP peptide variants
A 10-mer peptide derived from MBP is cleaved by
recombinant ADAM8 (Schlomann et al., 2002). To identify
specific amino acid requirements necessary for substrate
cleavage, peptide cleavage assays with various peptides
derived from the MBP cleavage site were performed
using the ProteaseSpot system. Assays were per-
formed in the absence or presence of 10 mM EDTA
(Figure 4). The fluorescence increase corresponding to
protease activity was monitored over 18 h. The fluores-
cence increase was expressed in units normalised to the
original bovine MBP peptide (s1). According to variable
fluorescence increases, it was concluded that ADAM8
cleaved the MBP peptide variants with different efficien-
cies, depending on the amino acid exchange. The pep-
tides bearing exchange of leucine for serine at position
P3 (peptide 2), of threonine for alanine at position P39
(peptide 8) and basic residues – arginine or lysine – for
a proline at position P1 (peptides 3 and 4) were cleaved
by ADAM8. Possibly, there was slightly enhanced cleav-
age for the variants with basic amino acids in position
P1 compared to the original MBP peptide. Amino
acid exchanges at positions P19 and P29 had significant
effects on peptide cleavage (peptides 5–7). Exchange of
a glutamine residue to an acidic glutamic acid residue in
position P19, as well as exchange of the basic lysine res-
idue in position P29 to either an acidic (glutamic acid)
or a neutral, aliphatic amino acid (valine) resulted in
decreased levels of peptide cleavage.
From these results, we conclude that basic residues in
positions P1 and P29 increase the efficiency of ADAM8
cleavage, whereas acidic residues in position P19 and P29
decrease cleavage.
ADAM8-dependent cleavage of APP in human
embryonic kidney 293 cells
We tested whether transfection of ADAM8 into human
embryonic kidney 293 cells increased secretion of
membrane-associated APP in a cell-based assay.
Human 293 cells were used that stably express a fusion
protein consisting of the reporter enzyme alkaline phos-
phatase (AP) tagged to the N-terminus of full-length APP
(AP-APP cells). Upon shedding of the APP ectodomain,
the soluble AP-tagged APP can easily be detected by
measuring the AP activity in the conditioned medium
(Lichtenthaler et al., 2003; Scho¨bel et al., 2006). The AP-
APP cells were transfected with constructs encoding
ADAM8 and inactive EQ-ADAM8, bearing a point muta-
tion by which glutamate residue 330 is exchanged to a
glutamine (Schlomann et al., 2002). This mutant form of
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Table 1 List of peptides and sequences used for screening ADAM8 candidate substrates.
Protein Peptide substrates ADAMs involved References
APP EVRHxQKLVFF ADAM8, 9, 10, 17, 33 Amour et al., 2002
b-Amyloid precursor protein Buxbaum et al., 1998
Accession no. P12023 Koike et al., 1999
Mohan et al., 2002
Zou et al., 2004
CD16 SLVWYHTAFS MP Harrison et al., 1991
Fc´-RIII, low-affinity IgG receptor PATTSSISLV
Accession no. P08508 VTITVQDPAT
TQHQxSKPVTI
CD23 SNQLAQxKxSQV MP, ADAM8 Fourie et al., 2003
Fc´-RII, low-affinity IgE receptor AEQKQMKAQD Marolewski et al., 1998
Accession no. P20693 LRNAQSQxNSK Mayer et al., 2002
VAKLWIEILI
CD40-L NSFEMQRGDE ADAM10 Amour et al., 2002
Accession no. P27548
CD163 HGTGHPxTLTA
Macrophage haemoglobin scavenger PKMTSESHGT
receptor DASIQCLPKM
Accession no. AAK16065 SDCGHKEDAS MP Droste et al., 1999
PAKPWSHSDC
ESSLWDCPAK
Fractalkine CX3CL1 QAATRRxQAVG ADAM17 Garton et al., 2001
Accession no. O35188
IL-1-RII TTVKEVSxSTFa ADAM8, 17 Amour et al., 2002
Interleukin-1 receptor type II Reddy et al., 2000
Accession no. P27931
KL PPVAASSLRN ADAM8, 9, 17, 33 Amour et al., 2002
Kit ligand Chesneau et al., 2003
Accession no. P20826 Mohan et al., 2002
Roghani et al., 1999
Zou et al., 2004
L-Selectin QETNRSxFSKI ADAM17 Peschon et al., 1998
Accession no. P18337
MBP YGSLPxQKAQGb ADAM8, 10, 28 Chantry et al., 1989
Myelin basic protein Howard et al., 2001
Accession no. P04370 Schlomann et al., 2002
PSGL-1 LIPVKQCLLI MP Davenpeck et al., 2000
P-Selectin glycoprotein ligand 1 TLPGSSDLIP
Accession no. Q62170 PGNSPAPTLP
KxKxGLIVTPGNc
HLPDSGLKxKxGc
TGF-a ADLLAVVAAS MP, ADAM17 Arribas et al., 1997
Transforming growth factor a AVVAASQxKxKQ Peschon et al., 1998
Accession no. P48030
TNF-a AxQTLTLRSxSS ADAM8, 9, 10, 17, 19 Amour et al., 2002
Tumour necrosis factor a Black et al., 1997
Accession no. P06804 Chesneau et al., 2003
Mohan et al., 2002
Moss et al., 1997
TNFRI NPQxDSGTAVL MP, ADAM17 Mohan et al., 2002
Tumour necrosis factor receptor 1 PPLANVTNPQ Pinckard et al., 1997
Accession no. P25118 CMKLCLPPPL Reddy et al., 2000
TNFRII PTLSAIPRTL MP, ADAM17 Mohan et al., 2002
Tumour necrosis factor receptor 2 APESPTLSAI Peschon et al., 1998
Accession no. P25119 Pinckard et al., 1997
Reddy et al., 2000
TRANCE VGPxQRFSGAP ADAM17, 19, 33 Chesneau et al., 2003
TNF-related activation-induced Lum et al., 1999
Cytokine Mohan et al., 2002
Accession no. O35235 Zou et al., 2004
Most sequences represent juxtamembraneous regions of the respective proteins. All peptide sequences were derived from
the mouse proteins and their Swiss-Prot/TrEMBL database accession numbers are listed (http://www.expasy.org/sprot/).
Arrows indicate the ADAM8 cleavage sites identified in this work by HPLC/mass spectrometry (except a,b,c). References on
cleavage of the homologous human peptides or respective membrane proteins are given in the right column. ClustalX was
used to determine homologous mouse peptides. MP, undefined metalloprotease.
aData from Amour et al. (2002) from homologous human peptide sequences.
bData from Schlomann et al. (2002).
cEstimated cleavage site.
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Figure 3 Peptide screening for potential ADAM8 substrates
using the ProteaseSpot system.
Peptides selected and ADAM8 cleavage sites are listed in Table
1. (A) The fluorescence increase based on proteolytic release of
the fluorophore was measured after 18 h. Fluorescence values
correspond to ADAM8 activity and are given as units normalised
to the myelin basic protein (MBP) peptide set to 1. Fluorescence
increase G1 is assumed to indicate significant cleavage (black
bars), and increases of 0.5–1 (grey bars) indicate cleavage with
lower efficiency. An increase F0.5 (white bars) indicates no pro-
tease-substrate relationship. Cleavage analysis was performed
with at least three independent ADAM8 preparations. Peptides
derived from APP, CD23, fractalkine CX3CL1, Fc´-RIII, L-selec-
tin, PSGL-1, TGF-a and TNF-a were cleaved significantly. (B)
Time-dependent increase in fluorescence after 2, 4, 6 and 18 h
of incubation of APP and CD23.1 peptides with ADAM8 prote-
ase. Values were corrected for the fluorescence values at ts0.
ADAM8 lacks prodomain removal and is catalytically
inactive in transfection assays (Naus et al., 2004). Addi-
tional controls were full-length ADAM10 and mock vector
(Figure 5). In AP-APP cells, ADAM8 was expressed in the
active full-length form (Figure 5B), with a 120-kDa band
for pro-ADAM8, a 90-kDa band for processed ADAM8
and a band representing the remnant form of ADAM8 of
ca. 60 kDa. In contrast, EQ-ADAM8 was not processed
because of the lack of autocatalytic prodomain removal
(Figure 5B; Schlomann et al., 2002). Compared to mock
transfected cells, active full-length ADAM8, but not the
inactive EQ-ADAM8, increased AP-APP shedding (Figure
5A), revealing that ADAM8 is able to cleave APP in vivo.
An identical result was observed by immunoblot analysis
of the same supernatants (Figure 5B) using monoclonal
antibody W02, which detects a-secretase-cleaved APP
(Ida et al., 1996). No significant changes in the amount
of full-length APP in the cell lysate were detected. This
shows that ADAM8 acts as a true a-secretase and
cleaves APP within the Ab domain, which fits well with
the in vitro cleavage site shown in Table 1.
Interestingly, ADAM8 stimulated APP release to an
extent comparable to ADAM10 (Figure 5A), which is one
of the candidate a-secretases that cleave APP (Lammich
et al., 1999). Thus, we have demonstrated that ADAM8
might contribute to a-secretase activity in vivo.
Discussion
Active ADAM8 was isolated from E. coli because of its
solubility and ability for autocatalytic prodomain removal.
The rate of autocatalysis leading to active ADAM8, how-
ever, was variable for different preparations. A similar
observation was made for ADAM8 expressed in COS
cells. This might be because autocatalysis is less efficient
with only the MP domain, whereas soluble ADAM8 con-
taining the disintegrin/cysteine-rich domain is completely
activated by prodomain removal (Schlomann et al.,
2002), but would likely cause solubility problems in E.
coli. In addition, in terms of inhibitory profile and sub-
strate specificity, ADAM8 from E. coli is indistinguishable
from soluble ADAM8 expressed in COS cells (Schlomann
et al., 2002; Naus et al., 2004), suggesting that glyco-
sylation of the ADAM8 protein in eukaryotes is not essen-
tial for catalytic activity. Similar to ADAM8 expressed in
COS cells, catalytic activity of E. coli-expressed ADAM8
was inhibited by EDTA, ortho-phenanthroline, and BB-94,
but not by marimastat (data not shown).
The ability of recombinant ADAM8 protease to cleave
10-mer peptides specifically was previously demonstrat-
ed (Amour et al., 2002), a prerequisite for screening
new potential substrates of ADAM8 protease by the
ProteaseSpot method. When selecting the peptides,
we considered that many ADAM substrates are cleaved
in juxtamembraneous regions. In addition, species con-
sistency was maintained by screening peptides derived
from mouse membrane proteins with mouse ADAM8 pro-
tease. In the present work, peptides derived from APP,
CD16, CD23, fractalkine CX3CL1, L-selectin, PSGL-1,
TGF-a, TNF-a, CD163, IL-1-RII, TNFRI and TRANCE
were significantly cleaved by ADAM8. Although it is dif-
ficult to transfer the peptide cleavage data to a physio-
logical situation, we can draw some conclusions. In the
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Figure 4 ADAM8-dependent cleavage of MBP peptide variants.
A peptide derived from the original MBP cleavage site and seven variant peptides were incubated with active ADAM8 protease.
Amino acid variants are given in bold letters. Average fluorescence values for each peptide were determined after 18 h. Values are
given as units normalised to the fluorescence increase for the original MBP peptide set to 1. The peptides with amino acid variations
in positions P19 and P29 were cleaved at significantly lower levels.
case of APP and TGF-a, ADAM8 cleavage sites match
with the reported sites. For CD16, as deduced from the
molecular mass of the released fragment reported
(Harrison et al., 1991), cleavage occurs in the most
membrane-proximal region. CD23 peptide cleavage sites
of ADAM8 match with those reported earlier from in vivo
cleavage (Mayer et al., 2002). Cleavage of L-selectin,
TGF-a, TNF-a and TNFRI occurs at cleavage sites slight-
ly ("1 or 2 amino acids) different from the physiological
sites (see references in Table 1), but sequences used for
the screening were derived from mouse sequences,
whereas most of the reported sequences refer to human
sequences, which have significant differences. For pep-
tides representing CD23 (SNQLAQxKxSQV) and TGF-a
(AVVAASQxKxKQ), ADAM8 cleavage was observed at
two adjacent amino acid residues, suggesting that
ADAM8 recognises the peptide, but cleaves with in-
accuracy.
Peptides derived from the cleavage site of MBP with
amino acid exchanges in positions P3–P39 were cleaved
by ADAM8 with different efficiencies. Assuming that
cleavage occurred at the same sites in all peptides, it
could be concluded for the MBP peptide that ADAM8
preferred a cleavage site with basic residues in positions
P1 and/or P29 and one without acidic residues around
the cleavage site, substantially not in position P19 and
P29. Mayer et al. (2002) suggested a similar hypothetical
consensus sequence XXR/KxXKX from human CD23
cleavage sites. A motif with QK at positions P19 and P29
in the peptides derived from APP, CD23 and MBP was
also present in the TGF-a peptide (AVVAASQxKxKQ),
suggesting physiological cleavage next to this motif.
Examination of the screened peptide collection revealed
regularity for cleaved peptides that were not applicable
for most of the non-cleaved peptides. The cleaved pep-
tides contained basic amino acid residues, whereas they
did not contain cysteine, methionine or tryptophan resi-
dues. Only five of the cleaved peptides (APP, IL-1-RII, L-
selectin, PSGL-1, TNFRI) contained acidic residues, and
only in the peptides representing IL-1-RII and TNFRI
were these acidic residues located in positions P3–P39
of proposed or determined cleavage sites.
Despite these regularities, ADAM substrate cleavage
sites are often promiscuous. In peptides derived from
TNF-a, three different cleavage sites for ADAM8, and two
different cleavage sites for ADAM9 and ADAM19, respec-
tively, were determined (Roghani et al., 1999; Amour et
al., 2002; Chesneau et al., 2003; Fourie et al., 2003).
Three different cleavage sites were sequenced for
ADAM9 in a KL peptide (Amour et al., 2002). The MBP
cleavage next to the QK motif was determined for
ADAM8, ADAM10 and ADAM28, emphasising the impor-
tance of this motif (Howard et al., 2001; Schlomann et
al., 2002). ADAM8, ADAM9 and ADAM33 cleaved an APP
peptide also at the QK motif, whereas ADAM10 and
ADAM17 cleaved the APP peptide two amino acids clos-
er to the C-terminus (Roghani et al., 1999; Amour et al.,
2002; Mohan et al., 2002; Zou et al., 2004). Comparison
of different substrate peptides also shows that different
ADAMs cleave the same substrate peptides, with the
cleavage sites being the same or in close proximity. This
could indicate that ADAM catalytic activities towards
peptides are similar, although kinetic properties could be
different. Further studies are necessary to determine sub-
strate specificity of ADAMs; however, based on our anal-
ysis, the likelihood of peptide cleavage by ADAM8 can
be predicted.
Based on cleavage of the APP protein by ADAM8, we
have in vivo evidence for ADAM8 as additional a-secre-
tase activity. APP is cleaved proteolytically in two distinct
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Figure 5 Shedding of APP by ADAM8 in 293 cells expressing
alkaline phosphatase (AP)-tagged APP (AP-APP cells).
Cells were transiently transfected with plasmids encoding
ADAM8 or ADAM10. As controls, cells were transfected with
mock vector (pTarget for the ADAM8 constructs and peak12 for
the ADAM10 construct) or with inactive ADAM8 (EQ-ADAM8).
(A) Quantification of AP-APP released into the conditionedmedi-
um relative to mock transfected cells. The mean and standard
deviation of two independent experiments are reported, each
one carried out in duplicate. (B) Western blot analysis confirming
the increase in AP-APP shedding upon transfection of ADAM8
and demonstrating the presence of processed ADAM8 protein:
120 kDa, pro-ADAM8; 90 kDa, processed ADAM8 lacking the
prodomain; and 60 kDa, ADAM8 lacking the pro- and metallo-
protease domain. In contrast, inactive EQ-ADAM8 is only pres-
ent in its proform. ADAM10-HA can also be detected in its
immature (upper band) and mature (lower band) forms. For
detection of the different proteins, the indicated antibodies were
used. AP-APPsa, soluble AP-APP generated by a-secretase;
AP-APPfl, full-length AP-APP; anti-HA, antibody against the C-
terminal HA-epitope tag of ADAM10; anti-BiPro, antibody
against the C-terminal BiPro-epitope tag of ADAM8.
pathways. In the amyloidogenic pathway, APP is cleaved
by b- and g-secretases to release amyloid b (Ab) pep-
tide, which forms non-soluble plaques (Haass, 2004). In
the anti-amyloidogenic pathway, APP is cleaved within
the amyloidogenic Ab domain by a-secretase to release
a non-amyloidogenic p3 peptide and, furthermore, a
large ectodomain of APP (APPsa) with neuroprotective
and memory-enhancing function (Furukawa et al., 1996;
Meziane et al., 1998; Mattson et al., 1999).
ADAM9, 10 and 17 are known as a-secretases and
cleave APP into non-amyloidogenic forms (Buxbaum et
al., 1998; Koike et al., 1999; Lammich et al., 1999), pre-
venting accumulation of amyloidogenic Ab peptides to
cerebral plaques that cause Alzheimer’s disease. In addi-
tion, ADAM8 and ADAM33 were shown to cleave a pep-
tide derived from the a-secretase cleavage site (Amour
et al., 2002; Zou et al., 2004). However, in co-transfection
experiments, ADAM33 did not cleave APP, but acted as
a negative regulator of APP shedding (Zou et al., 2004).
Moreover, no difference in the production of APP cleav-
age products in cultured hippocampal neurons from
ADAM9-deficient mice was detected compared to wild-
type neurons, arguing against an important role of
ADAM9 as a-secretase (Weskamp et al., 2002). However,
mice slightly overexpressing ADAM10 produced more
neurotrophic APPs and lower amounts of amyloidogenic
Ab peptides, suggesting that activation of ADAM10
a-secretase activity might be a therapeutic target for
treatment of Alzheimer’s disease (Postina et al., 2004).
Possibly, endogenous a-secretase activity is composed
of several ADAM enzymes (Asai et al., 2003). The upre-
gulation of ADAM8 expression in the nervous system
under inflammatory conditions supports the hypothesis
that ADAM8 belongs to this set of a-secretases (Schlo-
mann et al., 2000). ADAM8 might contribute to enhanced
production of neuroprotective APPs under pathological
conditions to compensate for neurodegeneration as an
additional a-secretase in the CNS during inflammation.
Taken together, our peptide analyses demonstrate that a
systematic ADAM substrate search should be based on
three criteria: (i) peptides are of sufficient length to rep-
resent the physiological cleavage sites of the substrates;
(ii) ADAMs cleave the peptide at a physiologically impor-
tant site; and (iii) the full-length protein is cleaved in the
same manner. Providing complete proof for the last cri-
terion will be the subject of further studies.
Materials and methods
Expression of soluble ADAM8 protease in E. coli
and purification
For ADAM8 expression in bacteria, the vector pASK-IBA3q(IBA,
Go¨ttingen, Germany) was used. This vector encodes a Strep-
tag that allows purification of the expressed protein by Strep-
Tactin MacroPrep Cartridges (IBA). The cDNA encoding the
mouse ADAM8 pro- and metalloprotease domain was amplified
with primers mA8_EcoRI.s 59-GAA TTC CTT GGC CTC TGG
CTG CTC AGC-39 and mA8_XhoI.as 59-CTC GAG GAT CTC CTG
AGG CTT AAA CTG AGG GAA GGA CAC GAA CCG GTT GAC
ATC TGG-39 containing the sequence for the BiPro-tag at the 39
end. The resulting cDNA was cloned into the respective restric-
tion sites of pASK-IBA3q and transformed into E. coli strain
BL21(DE3)pLysS. Bacteria were grown in the presence of tet-
racycline and ampicillin. For protein expression, bacteria were
grown in LB medium and induced at OD550 0.5 with 0.2 mg/ml
anhydrotetracycline (aTc, IBA) for 6 h at 308C with 50 mM ZnCl2
added to the medium. After harvesting the bacteria, pellets were
resuspended in 100 mM Tris, pH 8.0, 150 mM NaCl containing
1 mM phenylmethylsulfonyl fluoride and sonicated, and 5 mg/ml
DNase I and 10 mg/ml Rnase A were added. The mixture was
centrifuged twice at 13 000 g and once at 150 000 g before
applying the supernatants to Strep-Tactin cartridges and FPLC.
The purity of soluble ADAM8 was confirmed by SDS-PAGE and
protein concentrations were determined using BCA reagent
(Pierce, Heidelberg, Germany). Depending on the amount of
purified protein, FPLC eluates were concentrated with Amicon
Ultra Centrifugal Filter Units (Millipore, Bedford, MA, USA). Pro-
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teolytic activity was monitored using a fluorescent cleavage
assay with the peptide DNP-SHHGDQMAQKSQSTQI in the
absence or presence of ADAM inhibitors.
Protease assays
The ProteaseSpot system is based on peptides synthesised
on continuous cellulose membranes (JPT Peptide Technologies
GmbH, Berlin, Germany). Cellulose disks were cut into equiva-
lent pieces, activated in methanol for 5 min and subsequently
washed four times with HEPES buffer (20 mM HEPES, pH 7.4,
0.015% Brij-35). For the reactions, disks were incubated at 378C
with 100 ml of protease solution containing 50–100 ng of
ADAM8 protease, complete EDTA-free protease inhibitor cock-
tail (Roche Applied Science, Mannheim, Germany) and HEPES
buffer. For negative controls, 10 mM EDTA was added to the
samples. For positive controls, some peptides containing argi-
nine or lysine residues were incubated with a 0.1% (w/v) solution
of trypsin (Roche Applied Science).
Fluorescence (excitation at 325 nm and emission at 420 nm)
was measured initially, after 2, 4 and 6 h, and after 18 h using
a Perkin-Elmer LS50B luminescence spectrometer in black-
coated 96-well plates (Nunc, Wiesbaden, Germany).
Protease assays in solution were performed to analyse
the catalytic activity of purified ADAM8. The peptide DNP-
SHHGDQMAQKSQSTQI (100 mM) was incubated with 100 ml of
protease solution containing 50–100 ng of ADAM8 protease,
Complete EDTA-free protease inhibitor cocktail (Roche Applied
Science) and HEPES buffer (20 mM HEPES, pH 7.4, 0.015%Brij-
35), with 10 mM EDTA added to the negative controls. Immedi-
ately, and after 2 and 4 h of incubation, 30 ml samples were
mixed with 65 ml of HEPES buffer and 5 ml of 1% fluorescamine
(Sigma, Taufkirchen, Germany). Fluorescence (excitation at
386 nm and emission at 477 nm) was measured with a Perkin-
Elmer LS50B luminescence spectrometer in black-coated 96-
well plates (Nunc).
Western blot analysis
For Western blot sample preparation, total bacterial lysate pel-
lets with equal cell amounts were mixed with 1= SDS sample
buffer and sonicated. For inclusion body samples, the pellets
were resuspended in 100 mM Tris, pH 8.0, 150 mM NaCl. All
protein samples were mixed with 5= SDS sample buffer (50%
glycerol, 10% SDS, 100 mM b-mercaptoethanol, 0.05% bro-
mophenol blue in 250 mM Tris-HCl, pH 6.8), boiled for 10 min
and loaded onto 12.5% SDS-PAGE for soluble ADAM8 detection
and 7.5% SDS-PAGE for full-length ADAM8. After gel runs, the
proteins were blotted onto nitrocellulose transfer membranes
(Protran BA79, 0.1 mm pore size, Schleicher & Schuell, Dassel,
Germany) by semidry electroblotting. After control staining with
0.1% Ponceau S solution and blocking for 2 h with 5% skim
milk in TBS containing 0.1% Tween-20, proteins were analysed
by immunostaining. Mouse monoclonal anti-BiPro-tag antibody
(kindly provided by Dr. B.M. Jockusch, Braunschweig, Germany)
was diluted 1:25 in blocking buffer and incubated with the mem-
branes overnight at 48C. The detection of proteins was per-
formed with anti-mouse-IgG-horseradish peroxidase (1:8000,
1 h at RT, Sigma) using Lumi-LightPLUS (Roche Applied Sci-
ence) as the chemiluminescent substrate. Kodak X-OMAT X-ray
films were exposed to the emitted light. Exposure times depend-
ed on the intensity of the reaction. Fixing and developing of the
films was performed with Kodak X-ray Developer LX 24 and
Kodak X-ray Fixer AL4 (Eastman Kodak, Rochester, NY, USA).
For immunoblot detection of the different AP-APP species and
ADAM8 and ADAM10 expression in AP-APP cell lysates and
conditioned medium, aliquots of the conditioned medium and
cell lysates were boiled for 5 min at 958C with SDS sample buf-
fer. The samples were subjected to SDS-PAGE on an 8% SDS
gel. Proteins were transferred to a PVDF membrane and detect-
ed with the following antibodies: mouse monoclonal antibody
W02 against AP-APPsa (kind gift of K. Beyreuther; directed
against amino acids 1–16 of the Ab sequence; Ida et al., 1996);
polyclonal antibody 6687 against the C-terminus of APP detect-
ing full-length APP (Steiner et al., 2000); and antibody anti-BiPro,
detecting the C-terminal BiPro epitope tag of ADAM8 and EQ-
ADAM8. For detection of ADAM10-HA expression, the 6687-blot
was stripped and reprobed with a polyclonal anti-HA antibody
(Sigma).
Determination of peptide cleavage sites by mass
spectrometry
Peptide substrate (100 mM) in 250 ml of buffer containing 25 mM
Tris, pH 8.0 and 0.0006% Brij-35 was incubated with 300 ng of
ADAM8 metalloprotease domain isolated from a Strep-Tactin
affinity column. Incubations were performed at room tem-
perature or 378C for 4 h, after which an equal volume of 1%
heptafluorobutyric acid (HFBA) was added. Substrate was se-
parated from product by separation on a C18 column from
Vydac (Hesperia, CA, USA) using an acetonitrile/water gradient
with 0.1% HFBA. Further purification was performed using a
Shimadzu LC system (comprising a solvent degasser, two LC-
10A pumps and a SCL-10A system controller). The LC was cou-
pled to a QSTAR XL quadrupole time-of-flight tandem mass
spectrometer (ABI/MDS-Sciex, Toronto, Canada) equipped with
an electrospray source. LC was operated at a flow rate of
200 ml/min with a linear gradient as follows: 100% A held iso-
cratically for 2 min, linearly increased to 60% B over 18 min and
then increased to 100% B over 5 min. Mobile phase A consisted
of water/acetonitrile (98:2 v/v) with 0.1% acetic acid and mobile
phase B of acetonitrile/water (90:10 v/v) with 0.1% acetic acid.
A Zorbax C8 reverse-phase column (2.1=50 mm) was used for
all LC-MS analyses. MS data acquisition and analysis were per-
formed using the Analyst QS software.
Cell culture and transfections
Clonal 293-EBNA cells expressing AP-APP and Bcl-XL/CrmA
(clone SABC70) were generated and cultured as described by
Scho¨bel et al. (2006). Transfections were carried out using Lipo-
fectamine 2000 (Invitrogen, Groningen, Netherlands). The medi-
um was replaced with fresh medium 1 day after transfection.
After overnight incubation, conditioned medium and cell lysate
(in 50 mM Tris, pH 7.5, 150 mM NaCl, 1% Nonidet-P 40) were
collected. Aliquots of the conditioned medium were treated for
30 min at 658C to heat-inactivate the endogenous AP activity.
AP activity in the conditioned medium was measured as previ-
ously described (Lichtenthaler et al., 2003) and normalised to
the protein concentration in the cell lysate. The cDNA encoding
C-terminally HA-epitope tagged ADAM10 was cloned into the
expression vector peak12.
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